November 18, 2026
2 min read
Key takeaways:
- This was the first known carbapenem-resistant Salmonella outbreak in the U.S.
- Investigators identified eight infections in eight states, including three hospitalizations.
WASHINGTON — Researchers at IDWeek presented findings from the CDC investigation that traced the first known U.S. outbreak of carbapenem-resistant Salmonella infections to dietary supplements containing moringa leaf powder.
“You can imagine we tend to focus on things like foods, chicken, eggs and animal exposures because those are the common culprits for Salmonella outbreaks in the United States, but it’s definitely possible that we have gaps,” Louise Francois Watkins, MD, MPH, a medical officer in CDC’s Division of Foodborne, Waterborne and Environmental Diseases, said during a presentation. “I think this investigation kind of highlights one of those.”

The investigation began in December 2025 after a novel strain of Salmonella enterica serotype Newport submitted to CDC’s PulseNet database was found to carry the carbapenemase gene blaNDM-1 — “a rare finding among U.S. Salmonella isolates,” according to the abstract.
By January, investigators had identified additional genetically related isolates, suggesting a possible ongoing outbreak and prompting an investigation.
According to the investigation, state public health laboratories performed whole genome sequencing on collected isolates and the CDC assessed genetic relatedness and conducted antimicrobial susceptibility testing.
The investigation ultimately identified eight patients in eight states with infections reportedly occurring between Nov. 14, 2025, and Jan. 22, 2026. Three of the patients were hospitalized, and none died.
Antimicrobial susceptibility testing of five available clinical isolates revealed resistance to all first-line agents and carbapenems.
According to the researchers, the isolates were resistant to drugs in every antimicrobial class with established breakpoints, leaving no known susceptible treatment options.
During the investigation, patients were also interviewed about potential exposures — including dietary supplement use — while the FDA conducted traceback and product testing.
Five of the six patients interviewed reported consuming the same brand of dietary supplements containing Moringa oleifera leaf powder. The FDA’s traceback investigation identified a single supplier of moringa powder and the products were immediately recalled.
Healio previously reported that the moringa powder capsules were sold under the Rosabella brand, distributed by Ambrosia Brands. They are sold primarily online via the company’s website, as well as on Amazon, eBay, TikTok Shop and Shein. The company agreed to a prompt recall.
Based on the findings of the investigation, the researchers noted that dietary supplements may “represent a potential pathway for introducing resistant bacteria into the United States.”
